Evidence map›Paper›PMID 27716205›Full record

ArticleRespiratory research2016

Effects of inhaled high-molecular weight hyaluronan in inflammatory airway disease.

Adelaida Lamas, Jamie Marshburn, Vandy P Stober, Scott H Donaldson, Stavros Garantziotis

Abstract readComparative StudyLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Hyaluronan Ameliorates Viral Pneumonia in Mice and Humans by Inhibiting Transcription Factor E2F1.American journal of respiratory cell and molecular biology · 2026
    Article
  3. Article
  4. Biopolymeric Inhalable Dry Powders for Pulmonary Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Sugarcoating Lung Injury: A Novel Role for High-Molecular-Weight Hyaluronan in Pneumonia.American journal of respiratory and critical care medicine · 2019
    Article
  12. Hyaluronan in immune dysregulation and autoimmune diseases.Matrix biology : journal of the International Society for Matrix Biology · 2019
    Review
  13. High molecular weight hyaluronan ameliorates allergic inflammation and airway hyperresponsiveness in the mouse.American journal of physiology. Lung cellular and molecular physiology · 2018
    Article
  14. Instillation of hyaluronan reverses acid instillation injury to the mammalian blood gas barrier.American journal of physiology. Lung cellular and molecular physiology · 2018
    Article
  15. Observational
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Adelaida LamasHospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
Jamie MarshburnDivision of Intramural Research, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC, USA.
Vandy P StoberDivision of Intramural Research, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC, USA.
Scott H DonaldsonUniversity of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Stavros GarantziotisDivision of Intramural Research, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC, USA. garantziotis@niehs.nih.gov.ORCID 0000-0003-4007-375X

Funding

Program in Clinical Research, Clinical Support Services and Clinical TrainingZIDES102465 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI KIRSCHNER, LAWRENCE · 2009 to 2025
$84.7M
The Role of Hyaluronan And Inter-Alpha-Trypsin Inhibitor in Tissue InjuryZIAES102605 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI GARANTZIOTIS, STAVROS · 2009 to 2025
$22.6M
6 · The paper itself

Abstract

Cystic fibrosis (CF) is a chronic inflammatory disease that is affecting thousands of patients worldwide. Adjuvant anti-inflammatory treatment is an important component of cystic fibrosis treatment, and has shown promise in preserving lung function and prolonging life expectancy. Inhaled high molecular weight hyaluronan (HMW-HA) is reported to improve tolerability of hypertonic saline and thus increase compliance, and has been approved in some European countries for use as an adjunct to hypertonic saline treatment in cystic fibrosis. However, there are theoretical concerns that HMW-HA breakdown products may be pro-inflammatory. In this clinical pilot study we show that sputum cytokines in CF patients receiving HMW-HA are not increased, and therefore HMW-HA does not appear to adversely affect inflammatory status in CF airways.

Indexed as

Administration, InhalationAdolescentChildCystic FibrosisCytokinesFemaleHumansHyaluronic AcidMaleMolecular WeightPilot ProjectsPneumoniaSaline Solution, HypertonicSputumTreatment OutcomeYoung AdultCytokinesHyaluronic AcidSaline Solution, HypertonicAirway inflammationCystic fibrosisHyaluronanInduced sputum

Identifiers

PMID27716205
PMCPMC5048477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.